Aditya K Gupta1,2, John Cole3, David P Deutsch1,4, Peter A Everts5, Robert P Niedbalski1,6, Ratchathorn Panchaprateep1,7, Fabio Rinaldi1,8, Paul T Rose1,9, Rodney Sinclair10, James E Vogel1,11, Ryan J Welter12, Michael D Zufelt1,13, Carlos J Puig1,14. 1. International Society of Hair Restoration Surgery (ISHRS), Ad Hoc Committee on PRP. 2. Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada. 3. Cole Hair Transplant Group, Alpharetta, Georgia. 4. Bosley Medical, Beverly Hills, California. 5. EmCyte Corporation, Fort Myers, Florida. 6. Northwest Hair Restoration, Tacoma, Washington. 7. Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. 8. International Hair Research Foundation, Italy. 9. Hair Transplant Institute Miami, Coral Gables, Florida. 10. Sinclair Dermatology, Melbourne, Australia. 11. Division of Plastic Surgery, Department of Surgery, The Johns Hopkins Hospital and School of Medicine, Baltimore, Maryland. 12. New England Center for Hair Restoration, Westwood, Massachusetts. 13. Hair Restoration Center of Utah, Salt Lake City, Utah. 14. Physicians Hair Restoration Center, Houston, Texas.
Abstract
BACKGROUND: Platelet-rich plasma (PRP) treatment may encourage hair growth by promoting cellular maturation, differentiation, and proliferation. OBJECTIVE: The objective of this study was to evaluate the effectiveness of PRP as a treatment for androgenetic alopecia (AGA). MATERIALS AND METHODS: A literature search combined with meta-analysis was used to calculate the overall standardized mean difference (SMD) in hair density in patients treated with PRP injections in comparison with baseline and placebo treatment. Chi squared analysis and Fisher exact test were used to investigate variation in protocols. RESULTS: The overall SMD in hair density was 0.58 (95% confidence interval [CI]: 0.35-0.80) and 0.51 (95% CI: 0.23-0.80, p < .0004) in favor of PRP treatment when compared with baseline and placebo treatment, respectively. CONCLUSION: Platelet-rich plasma is beneficial in the treatment of AGA. It is recommended that 3 monthly sessions of PRP (once monthly ×3 treatments) be used followed by a 3- to 6-month maintenance period.
BACKGROUND: Platelet-rich plasma (PRP) treatment may encourage hair growth by promoting cellular maturation, differentiation, and proliferation. OBJECTIVE: The objective of this study was to evaluate the effectiveness of PRP as a treatment for androgenetic alopecia (AGA). MATERIALS AND METHODS: A literature search combined with meta-analysis was used to calculate the overall standardized mean difference (SMD) in hair density in patients treated with PRP injections in comparison with baseline and placebo treatment. Chi squared analysis and Fisher exact test were used to investigate variation in protocols. RESULTS: The overall SMD in hair density was 0.58 (95% confidence interval [CI]: 0.35-0.80) and 0.51 (95% CI: 0.23-0.80, p < .0004) in favor of PRP treatment when compared with baseline and placebo treatment, respectively. CONCLUSION: Platelet-rich plasma is beneficial in the treatment of AGA. It is recommended that 3 monthly sessions of PRP (once monthly ×3 treatments) be used followed by a 3- to 6-month maintenance period.
Authors: Anna Starzyńska; Magdalena Kaczoruk-Wieremczuk; Michele Antonio Lopez; Pier Carmine Passarelli; Paulina Adamska Journal: Int J Environ Res Public Health Date: 2021-12-18 Impact factor: 3.390